Emerging Growth Drivers in the Hereditary Transthyretin Amyloidosis Market Landscape: Rising Geriatric Population Driving The Growth Of The Market Due To Increasing Disease Prevalence
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Are the Key Projections for the CAGR of the Hereditary Transthyretin Amyloidosis Market Size From 2025 to 2034?
The market size for hereditary transthyretin amyloidosis has shown substantial growth in recent times. Projected growth indicates an increase from $1.36 billion in 2024 to $1.49 billion in 2025, showcasing a compound annual growth rate (CAGR) of 9.3%. Factors such as a surge in occurrences of this condition, escalated research and development initiatives, rising cases of cardiac amyloidosis, increased understanding of the disorder, and improvement in the healthcare infrastructure have contributed to the growth during the historic period.
The market size for hereditary transthyretin amyloidosis is predicted to experience robust expansion in the nearing years. The expectation is for it to reach $2.09 billion in 2029 at a Compound Annual Growth Rate (CAGR) of 9.0%. This anticipated growth during the projection period can be ascribed to factors such as an increasing elderly population, growing disposable incomes, a higher frequency of hereditary transthyretin amyloidosis cases, proliferation in the production of new medicines, and an uptick in genetic testing. Significant trends to watch during this forecast period encompass progressive treatment products, advancements in diagnostic methods, leaps in drug development, a surge in demand for efficient therapies, and breakthroughs in medical technology.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22003&type=smp
Which Primay Drivers Are Accelerating Growth in the Hereditary Transthyretin Amyloidosis Market?
The expansion of the hereditary transthyretin amyloidosis market is anticipated to be fuelled by the growing demographic of older individuals. This group, often in need of specialized healthcare as they age, is generally comprised of those aged 65 and above. Contributing factors to the growth of this demographic include improvements in healthcare and living standards, which have boosted life expectancy. Hereditary transthyretin amyloidosis (hATTR) significantly affects this population, leading to progressive neuropathy and cardiomyopathy, thereby increasing the rate of illness in older individuals. For example, data from the US-based non-profit, the Population Reference Bureau, revealed in January 2024 that the population of those aged 65 and over in the US is projected to grow from 58 million in 2022 to 82 million by 2050, a leap of 47%. Consequently, the rising number of elderly individuals is propelling the growth of the hereditary transthyretin amyloidosis market.
Which Primary Segments of the Hereditary Transthyretin Amyloidosis Market Are Driving Growth and Industry Transformations?
The hereditary transthyretin amyloidosismarket covered in this report is segmented –
1) By Type: Oral; Subcutaneous Injection; Other Types
2) By Drug Class: RNAi Agents (Patisiran); Small Interfering RNAs (siRNAs) (Vutrisiran)
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies
4) By Application: Hospital; Clinic; Other Applications
Subsegments:
1) By Oral: Tafamidis; Diflunisal; Experimental Oral Therapies
2) By Subcutaneous Injection: Patisiran; Inotersen; Vutrisiran
3) By Other Types: Intravenous Therapies; Gene Silencing Therapies; CRISPR-Based Therapies
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=22003&type=smp
Which Regions Are Key Players in the Growth of the #Which Primay Drivers Are Accelerating Growth in the Hereditary Transthyretin Amyloidosis Market?# Market?
North America was the largest region in the hereditary transthyretin amyloidosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary transthyretin amyloidosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Which Technological Trends Are Reshaping the Hereditary Transthyretin Amyloidosis Industry Dynamics?
Leading corporations in the hereditary transthyretin amyloidosis market are introducing new therapeutics, including RNAi therapeutics, aimed at reducing the creation of transthyretin (TTR) protein. RNAi therapeutics represent a category of medicines that utilize RNA interference technology to mute specific genes, thus decreasing the generation of proteins that cause disease. For example, in October 2024, US-based biopharmaceutical firm Alnylam Pharmaceuticals, Inc., presented a supplemental new drug application (sNDA) to the US FDA for the treatment of transthyretin amyloidosis with cardiomyopathy using Vutrisiran (AMVUTTRA). This application highlights their cutting-edge RNAi therapeutic strategy, crafted to decrease the production of transthyretin (TTR) protein, a crucial contributor to disease progression. The possibility to administer Vutrisiran subcutaneously makes it a more comfortable and patient-friendly alternative compared to traditional intravenous treatments, thereby potentially revolutionizing the treatment for individuals suffering from this severe ailment.
View the full report here:
What Parameters Are Used to Define the Hereditary Transthyretin Amyloidosis Market?
Hereditary transthyretin amyloidosis is a rare, inherited disorder caused by mutations in the TTR gene, leading to the misfolding and accumulation of transthyretin protein as amyloid deposits in organs. This condition primarily affects the nervous system, heart, and other tissues, causing progressive neuropathy and cardiomyopathy.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22003
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
